FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285013092> ?p ?o ?g. }

• W4285013092 endingPage "e1008" @default.
• W4285013092 startingPage "e1000" @default.
• W4285013092 abstract "Peripheral neuropathy is a common treatment-emergent side effect during the treatment of newly diagnosed multiple myeloma. Although bortezomib is most commonly implicated, real-world data suggest that lenalidomide and dexamethasone (VRd) and autologous stem cell transplantation (ASCT) may also contribute to neuropathy and health-related quality of life (HRQoL).The Multiple Myeloma Research Foundation (MMRF) CoMMpass Registry was queried for all patients who received frontline VRd or bortezomib, cyclophosphamide and dexamethasone (VCd). Incidence of neuropathy and patient-reported HRQoL outcomes over the first 12 months after diagnosis were compared between patients receiving VRd or VCd with or without early ASCT before 6 months.There were 368 and 191 patients treated with VRd and VCd, respectively. VRd with early ASCT was associated with worse grade 1 neuropathy compared to VRd without early ASCT, as well as compared to VCd with early ASCT. There were no differences in neuropathy between VRd and VCd without early ASCT, and no differences in grade ≥2 neuropathy. There were significant improvements in HRQoL between baseline and 12 months in both VRd and VCd cohorts, regardless of early ASCT. Development of neuropathy was not associated with decrements in progression-free survival or overall survival.In this longitudinal database analysis, there were no differences in grade ≥2 neuropathy between VRd and VCd frontline induction, and overall HRQoL significantly improved across all cohorts. However, differences in grade 1 neuropathy between VRd and VCd induction suggest that lenalidomide and high-dose melphalan may augment the risk of neuropathy in newly diagnosed multiple myeloma." @default.
• W4285013092 created "2022-07-12" @default.
• W4285013092 creator A5057911528 @default.
• W4285013092 creator A5058665273 @default.
• W4285013092 creator A5069593908 @default.
• W4285013092 date "2022-11-01" @default.
• W4285013092 modified "2023-09-30" @default.
• W4285013092 title "Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma" @default.
• W4285013092 cites W1992538067 @default.
• W4285013092 cites W2016146859 @default.
• W4285013092 cites W2049746143 @default.
• W4285013092 cites W2050104081 @default.
• W4285013092 cites W2068889400 @default.
• W4285013092 cites W2070790769 @default.
• W4285013092 cites W2117237065 @default.
• W4285013092 cites W2131076472 @default.
• W4285013092 cites W2141105112 @default.
• W4285013092 cites W2169183166 @default.
• W4285013092 cites W2169336006 @default.
• W4285013092 cites W2186804713 @default.
• W4285013092 cites W2473107683 @default.
• W4285013092 cites W2567188480 @default.
• W4285013092 cites W2600519230 @default.
• W4285013092 cites W2791674076 @default.
• W4285013092 cites W2796267538 @default.
• W4285013092 cites W2899046741 @default.
• W4285013092 cites W2904294860 @default.
• W4285013092 cites W2930686294 @default.
• W4285013092 cites W2972305086 @default.
• W4285013092 cites W3006419152 @default.
• W4285013092 cites W3006850578 @default.
• W4285013092 cites W3012199294 @default.
• W4285013092 cites W3019889711 @default.
• W4285013092 cites W3082053425 @default.
• W4285013092 cites W3112426988 @default.
• W4285013092 cites W3129616378 @default.
• W4285013092 cites W3136849454 @default.
• W4285013092 cites W3157828882 @default.
• W4285013092 doi "https://doi.org/10.1016/j.clml.2022.07.002" @default.
• W4285013092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35922273" @default.
• W4285013092 hasPublicationYear "2022" @default.
• W4285013092 type Work @default.
• W4285013092 citedByCount "2" @default.
• W4285013092 countsByYear W42850130922023 @default.
• W4285013092 crossrefType "journal-article" @default.
• W4285013092 hasAuthorship W4285013092A5057911528 @default.
• W4285013092 hasAuthorship W4285013092A5058665273 @default.
• W4285013092 hasAuthorship W4285013092A5069593908 @default.
• W4285013092 hasConcept C126322002 @default.
• W4285013092 hasConcept C134018914 @default.
• W4285013092 hasConcept C141071460 @default.
• W4285013092 hasConcept C143998085 @default.
• W4285013092 hasConcept C2776063141 @default.
• W4285013092 hasConcept C2776364478 @default.
• W4285013092 hasConcept C2777478702 @default.
• W4285013092 hasConcept C2778684742 @default.
• W4285013092 hasConcept C2779050716 @default.
• W4285013092 hasConcept C2779901536 @default.
• W4285013092 hasConcept C2780401358 @default.
• W4285013092 hasConcept C555293320 @default.
• W4285013092 hasConcept C71924100 @default.
• W4285013092 hasConceptScore W4285013092C126322002 @default.
• W4285013092 hasConceptScore W4285013092C134018914 @default.
• W4285013092 hasConceptScore W4285013092C141071460 @default.
• W4285013092 hasConceptScore W4285013092C143998085 @default.
• W4285013092 hasConceptScore W4285013092C2776063141 @default.
• W4285013092 hasConceptScore W4285013092C2776364478 @default.
• W4285013092 hasConceptScore W4285013092C2777478702 @default.
• W4285013092 hasConceptScore W4285013092C2778684742 @default.
• W4285013092 hasConceptScore W4285013092C2779050716 @default.
• W4285013092 hasConceptScore W4285013092C2779901536 @default.
• W4285013092 hasConceptScore W4285013092C2780401358 @default.
• W4285013092 hasConceptScore W4285013092C555293320 @default.
• W4285013092 hasConceptScore W4285013092C71924100 @default.
• W4285013092 hasFunder F4320306439 @default.
• W4285013092 hasFunder F4320310308 @default.
• W4285013092 hasFunder F4320332161 @default.
• W4285013092 hasFunder F4320337351 @default.
• W4285013092 hasIssue "11" @default.
• W4285013092 hasLocation W42850130921 @default.
• W4285013092 hasLocation W42850130922 @default.
• W4285013092 hasOpenAccess W4285013092 @default.
• W4285013092 hasPrimaryLocation W42850130921 @default.
• W4285013092 hasRelatedWork W1576670771 @default.
• W4285013092 hasRelatedWork W2074205062 @default.
• W4285013092 hasRelatedWork W2087944168 @default.
• W4285013092 hasRelatedWork W2124042268 @default.
• W4285013092 hasRelatedWork W2470933183 @default.
• W4285013092 hasRelatedWork W2605951469 @default.
• W4285013092 hasRelatedWork W2738602720 @default.
• W4285013092 hasRelatedWork W3127479238 @default.
• W4285013092 hasRelatedWork W37180177 @default.
• W4285013092 hasRelatedWork W4362657418 @default.
• W4285013092 hasVolume "22" @default.
• W4285013092 isParatext "false" @default.
• W4285013092 isRetracted "false" @default.
• W4285013092 workType "article" @default.